옵션 체인은 다양한 행사가격과 만기일에 대한 Intellia Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Intellia Therapeutics에 대한 시장 심리를 평가합니다..

Intellia Therapeutics (NASDAQ:NTLA) 주식, 옵션 체인

INTELLIA THERAPEUTICS INC

Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Ark Invest Cathie Wood

Economics

ADPT

ARKG

ARKK

ARKQ

NTLA

TSLA

금요일에, 캐시 우드가 이끄는 아크 인베스트(Ark Invest)가 몇 가지 중요한 거래를 했다. 이 중 가장 눈에 띄는 것은 테슬라(NASDAQ:TSLA), 10X 지노믹스(NASDAQ:TXG), 인텔리아 테라퓨틱스(NASDAQ:NTLA), 3D 시스템즈(NYSE:DDD), 및 어댑티브 바이오테크놀로지스(NASDAQ:ADPT)에서의 거래이다.

아크 인베스트, 일론 머스크가 트럼프 행정부에서 떠나자 테슬라 매각 계속 진행 중

Cathie Wood Smelling AI Opportunity? Ark Invest Buys Tempus AI Dip, Scoops Up Over $13 M Worth Of Stock

Equities

News

Markets

ETFs

ARKF

ARKW

CDNA

GTLB

IBTA

PATH

PRME

RBLX

RPTX

2025년 3월 14일 금요일, 캐시 우드가 이끄는 아크 인베스트가 깃랩(NASDAQ:GTLB), 인텔리아 테라퓨틱스(NGM:NTLA), 프라임 메디슨(NGM:PRME), 유아이패스(NYSE:PATH), 아이보타(NYSE:IBTA), 로블록스(NYSE:RBLX), 리페어 테라퓨틱스(NASDAQ:RPTX) 및 케어DX(NASDAQ:CDNA)에 대해 큰 매매를 했다.

아크 인베스트: 유아이패스와 로블록스 주식을 계속 처분, 깃랩과 아이보타를 매수

Cathie Wood Takes Profit On Hot AI Stock Palantir Again, Continues To Sell Block Shares Amid Bitcoin Buzz

ABSI

ACCD

ARKX

ESLT

ILMN

OKLO

화요일(21일) 캐시 우드가 이끄는 아크 인베스트는 애콜레이드(NASDAQ:ACCD), 디어(NYSE:DE), 인텔리아 테라퓨틱스(NASDAQ:NTLA), 유아이패스(NYSE:PATH), 카메코(NYSE:CCJ), 오클로(NYSE:OKLO), 일루미나(NASDAQ:ILMN), 엘빗 시스템즈(NASDAQ:ESLT), 앱사이(NASDAQ:ABSI)와 관련된 상당한 거래를 진행했다. 

아크 인베스트, 트럼프의 정책에 따라 방산주·에너지주 투자

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics Inc

WIIM

BRCC

BRC shares are trading lower after the company announced it has priced a $35 million public offering of common stock.

ACTU

Actuate Therapeutics Initiates Planning Of Phase 2 Trial Of Elraglusib In Children, Adolescents, And Adults With Refractory/Resistant Ewing Sarcoma

HYPR

Hyperfine shares are trading higher after the company announced the first commercial sales of its Swoop system, powered by Optive AI software.

Actuate Therapeutics Announces End Of Phase 1 Portion Of Clinical Study Evaluating Elraglusib Monotherapy Or In Combination With Irinotecan, Irinotecan Plus Temozolomide, Or With Cyclophosphamide Plus Topotecan In Pediatric Patients With Refractory Malignancies

Offerings

NioCorp Prices $45.0M Public Offering Of 13,850,000 Shares At $3.25/Share

Guidance

IQST

IQSTEL Jun. Revenue $27.3M, Up From $23.7M In May; Reports Prelim. 1H Revenue Of $128.8M

Swiss pharmaceutical giant Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported second-quarter 2025 earnings on Thursday and raised its full-year earnings forecast.
Quarterly sales reached $14.05 billion, almost in line with the analysts&#8217; consensus <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimate of $14.06 billion</a>.
Net sales <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-reports-strong-q2-double-digit-sales-growth-and-core-margin-expansion-raises-fy-2025-core-operating-income-guidance" rel="noreferrer noopener">grew</a> 12% year over year (+11% on constant currency or cc) with core operating income up 20% to $5.93 billion (+21% on constant currency).
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46292859/novartis-gets-swiss-approval-for-first-malaria-drug-for-babies" rel="noreferrer noopener">Novartis Gets Swiss Approval For First Malaria Drug For Babies</a>
Sales growth driven by performance from breast cancer treatment, Kisqali ($1.18 billion, +64% cc), Entresto ($2.36 billion, +22% cc), multiple sclerosis drug, Kesimpta ($1.08 billion, +33% cc), Scemblix ($298 million, +79% cc), Leqvio ($298 million, +61% cc), and Pluvicto ($454 million, +30% cc).
Novartis reported adjusted earnings of $2.42 per share, beating the consensus of $2.38.
The company also announced a substantial share buyback program. Novartis said it is initiating a share buyback of up $10 billion to be completed by year-end 2027.
&#8220;Our robust balance sheet and confidence in our mid- and long-term growth enable us to initiate an up-to $10 billion share buyback as part of our commitment to balanced capital allocation,&#8221; stated CEO Vas Narasimhan in a statement on Thursday.
Earlier in July, Novartis released topline results from the Phase 3 GCAptAIN study evaluating Cosentyx (secukinumab) for newly diagnosed or relapsing <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">giant cell arteritis (GCA)</a>.
The study evaluated Cosentyx with a 26-week steroid taper and compared it to a placebo plus a 52-week steroid taper.&nbsp;Cosentyx did not demonstrate a statistically significant improvement in sustained remission at <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46243947/novartis-cosentyx-fails-late-stage-giant-cell-arteritis-trial" rel="noreferrer noopener">Week 52 compared to placebo</a>.
<h2 class="wp-block-heading">Outlook</h2>
For fiscal year 2025, Novartis reaffirms that net sales will grow in the high single digits. 2025 core operating income is expected to grow in the low teens, compared to the low double <a target="_blank" href="https://www.benzinga.com/25/04/45075714/novartis-q1-earnings-beat-street-view-ceo-confident-to-deliver-upgraded-2025-guidance" rel="noreferrer noopener">digits forecasted earlier</a>.
&#8220;We continue to assume Entresto US generic entry in mid-2025 for forecasting purposes, though the timing of generic entry is subject to ongoing IP and regulatory litigation,&#8221; Novartis said in the release.
<h2 class="wp-block-heading">Management Update</h2>
In a separate announcement, Novartis provided a key leadership update: Chief Financial Officer Harry Kirsch will <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-appoints-mukul-mehta-chief-financial-officer-harry-kirsch-retires-after-22-years-company" rel="noreferrer noopener">retire</a> in March 2026, concluding an impressive 22-year tenure at the company, including 12 years in the CFO role since 2013.
He will be succeeded by Mukul Mehta, who currently serves as the company&#8217;s head of business planning and analysis, digital finance, and tax.
Price Action: NVS stock is trading lower by 1.71% to $116.35 during the premarket session at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46463670/supermicro-launches-new-ai-servers-with-intel-xeon-6-chips" target="_blank" rel="noreferrer noopener">Supermicro Launches New AI Servers With Intel Xeon 6 Chips</a></li>
</ul>
Photo via Shutterstock

Biotech

Earnings

Large Cap

Health Care

Buybacks

Management

Movers

General

Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback

Nano Labs shares are trading higher after the company announced it has appointed a new CEO to lead the global crypto reserve strategy of its subsidiary.

Morgan Stanley analyst Kristine Liwag maintains Teledyne Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) with a Equal-Weight and raises the price target from $535 to $580.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Teledyne Technologies, Raises Price Target to $580

ATHR

Aether Holdings' Alpha Edge Media Acquires Digital Asset Research And Publication, AltcoinInvesting.co

BPMC

Trading Halt: Halt status updated at 8:45:00 AM ET: Quotation Resumption: News and Resumption Times

Morgan Stanley analyst Kristine Liwag maintains Curtiss-Wright (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) with a Overweight and raises the price target from $405 to $550.

Morgan Stanley Maintains Overweight on Curtiss-Wright, Raises Price Target to $550

Stock Split

LCID

Lucid Files Preliminary Proxy Statement To Initiate Plan For 1-for-10 Reverse Stock Split

NUWE

Nuwellis shares are trading lower after the company announced it has terminated its REVERSE-HF clinical trial to prioritize resources and redirect investment.

INSE

Inspired Entertainment Expands Long-Term Partnership With William Hill To Deliver Comprehensive Upgrade To William Hill's Virtual Sports Offering Across Its UK Retail Estate

Oklo shares are trading higher after the company completed the U.S. Nuclear Regulatory Commission's pre-application readiness assessment for Phase 1 of its combined license application for the Aurora Powerhouse.

Stifel analyst Jeffrey Stantial maintains Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) with a Hold and raises the price target from $81 to $92.

MCRI

Stifel Maintains Hold on Monarch Casino & Resort, Raises Price Target to $92

B. Riley Securities analyst Mike Crawford maintains TTM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTMI#NASDAQ">TTMI</a>) with a Buy and raises the price target from $36 to $50.

TTMI

B. Riley Securities Maintains Buy on TTM Technologies, Raises Price Target to $50

BTCT

BTC Digital Announces Transformative, Strategic Shift To Fully Embrace Ethereum As Core Asset And Operational Foundation; Closes $6M Financing Round, Adds New $1M ETH Position

Truist Securities analyst Matthew Coad maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Buy and raises the price target from $58 to $72.

AFRM

Truist Securities Maintains Buy on Affirm Holdings, Raises Price Target to $72

Legal

Press Releases

Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – NTLA

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Comments

Intellia Therapeutics

Intellia Therapeutics (NTLA) 옵션

Intellia Therapeutics (NASDAQ:NTLA) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌